Innoviva Current Ratio 2010-2023 | INVA

Innoviva current ratio from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Innoviva Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2023-12-31 $0.34B $0.04B 9.03
2023-09-30 $0.31B $0.04B 8.43
2023-06-30 $0.32B $0.04B 8.21
2023-03-31 $0.30B $0.04B 7.77
2022-12-31 $0.44B $0.14B 3.29
2022-09-30 $0.46B $0.16B 2.77
2022-06-30 $0.40B $0.13B 3.18
2022-03-31 $0.32B $0.11B 2.91
2021-12-31 $0.31B $0.01B 54.02
2021-09-30 $0.24B $0.00B 75.82
2021-06-30 $0.15B $0.01B 27.60
2021-03-31 $0.37B $0.00B 98.04
2020-12-31 $0.34B $0.01B 55.98
2020-09-30 $0.57B $0.00B 146.75
2020-06-30 $0.50B $0.01B 92.39
2020-03-31 $0.47B $0.00B 166.87
2019-12-31 $0.43B $0.01B 80.29
2019-09-30 $0.37B $0.00B 110.18
2019-06-30 $0.32B $0.01B 42.50
2019-03-31 $0.25B $0.00B 66.02
2018-12-31 $0.20B $0.01B 34.92
2018-09-30 $0.12B $0.00B 28.18
2018-06-30 $0.18B $0.01B 26.36
2018-03-31 $0.11B $0.00B 27.85
2017-12-31 $0.20B $0.04B 5.77
2017-09-30 $0.22B $0.03B 6.71
2017-06-30 $0.20B $0.03B 7.31
2017-03-31 $0.21B $0.02B 10.47
2016-12-31 $0.20B $0.02B 9.88
2016-09-30 $0.19B $0.02B 12.47
2016-06-30 $0.19B $0.02B 13.02
2016-03-31 $0.20B $0.01B 18.52
2015-12-31 $0.21B $0.01B 15.89
2015-09-30 $0.22B $0.01B 19.84
2015-06-30 $0.24B $0.01B 19.97
2015-03-31 $0.26B $0.01B 23.90
2014-12-31 $0.25B $0.01B 18.33
2014-09-30 $0.27B $0.04B 7.58
2014-06-30 $0.35B $0.05B 7.06
2014-03-31 $0.39B $0.04B 8.82
2013-12-31 $0.48B $0.08B 5.73
2013-09-30 $0.52B $0.04B 13.51
2013-06-30 $0.46B $0.04B 11.83
2013-03-31 $0.48B $0.03B 16.11
2012-12-31 $0.26B $0.03B 8.71
2012-09-30 $0.28B $0.03B 10.43
2012-06-30 $0.30B $0.03B 11.77
2012-03-31 $0.20B $0.03B 7.99
2011-12-31 $0.25B $0.05B 5.38
2011-09-30 $0.27B $0.04B 6.76
2011-06-30 $0.29B $0.04B 8.20
2011-03-31 $0.30B $0.03B 8.99
2010-12-31 $0.32B $0.04B 7.90
2010-09-30 $0.20B $0.04B 5.43
2010-06-30 $0.22B $0.04B 6.01
2010-03-31 $0.23B $0.04B 6.53
2009-12-31 $0.16B $0.04B 4.16
2009-09-30 $0.16B $0.04B 4.14
2009-06-30 $0.18B $0.04B 4.57
2009-03-31 $0.19B $0.04B 5.08
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.930B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $721.736B 120.19
Novo Nordisk (NVO) Denmark $562.737B 46.36
Johnson & Johnson (JNJ) United States $358.552B 14.27
Merck (MRK) United States $319.493B 84.10
AbbVie (ABBV) United States $296.619B 15.08
AstraZeneca (AZN) United Kingdom $215.324B 19.08
Novartis AG (NVS) Switzerland $199.963B 13.85
Pfizer (PFE) United States $149.151B 14.39
Sanofi (SNY) $117.880B 10.61